 Antiparkinson Agents
"Antiparkinson Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
| Descriptor ID |
D000978
|
| MeSH Number(s) |
D27.505.954.427.090.050
|
| Concept/Terms |
Antiparkinson Agents- Antiparkinson Agents
- Agents, Antiparkinson
- Antiparkinsonian Agents
- Agents, Antiparkinsonian
- Antiparkinsonians
- Antiparkinson Drugs
- Drugs, Antiparkinson
|
Below are MeSH descriptors whose meaning is more general than "Antiparkinson Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiparkinson Agents".
This graph shows the total number of publications written about "Antiparkinson Agents" by people in UAMS Profiles by year, and whether "Antiparkinson Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 1 | 1 | | 2023 | 0 | 3 | 3 | | 2019 | 2 | 1 | 3 | | 2018 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2014 | 0 | 2 | 2 | | 2013 | 2 | 0 | 2 | | 2009 | 2 | 1 | 3 | | 2002 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antiparkinson Agents" by people in Profiles over the past ten years.
-
Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vara J, Isaacson SH, Kieburtz K, LeWitt PA, Lopez-Manzanares L, Olanow CW, Poewe W, Sarva H, Yardeni T, Adar L, Salin L, Lopes N, Sasson N, Case R, Rascol O. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol. 2024 May; 23(5):465-476.
-
Espay AJ, Hauser RA, Dhall R, Thakkar S, Cloud L, Zeitlin L, Banisadr G, Fisher S, Visser H. Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study. Mov Disord. 2024 Feb; 39(2):428-432.
-
Gupta HV, Lenka A, Dhamija RK, Fasano A. A video-atlas of levodopa-induced dyskinesia in Parkinson's disease: terminology matters. Neurol Sci. 2024 Apr; 45(4):1389-1397.
-
Olanow CW, Hauser RA, Burdick DJ, Dhall R, de Marcaida JA, Gil RA, Kreitzman DL, Elmer LW, McGarry A, Kieburtz K. A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease. Mov Disord. 2024 Feb; 39(2):350-359.
-
Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C. Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020 02; 71:4-10.
-
Gupta HV, Lyons KE, Pahwa R. Old Drugs, New Delivery Systems in Parkinson's Disease. Drugs Aging. 2019 09; 36(9):807-821.
-
Santiago A, Langston JW, Gandhy R, Dhall R, Brillman S, Rees L, Barlow C. Qualitative Evaluation of the Personal KinetiGraphTM Movement Recording System in a Parkinson's Clinic. J Parkinsons Dis. 2019; 9(1):207-219.
-
Paul SS, Schaefer SY, Olivier GN, Walter CS, Lohse KR, Dibble LE. Dopamine Replacement Medication Does Not Influence Implicit Learning of a Stepping Task in People With Parkinson's Disease. Neurorehabil Neural Repair. 2018 12; 32(12):1031-1042.
-
Leehey M, Luo S, Sharma S, Wills AA, Bainbridge JL, Wong PS, Simon DK, Schneider J, Zhang Y, P?rez A, Dhall R, Christine CW, Singer C, Cambi F, Boyd JT. Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. Neurology. 2017 Oct 24; 89(17):1789-1794.
-
Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016 Apr 05; 86(14 Suppl 1):S13-24.
-
Lotia M, Jankovic J. New and emerging medical therapies in Parkinson's disease. Expert Opin Pharmacother. 2016; 17(7):895-909.
-
Weiss D, Klotz R, Govindan RB, Scholten M, Naros G, Ramos-Murguialday A, Bunjes F, Meisner C, Plewnia C, Kr?ger R, Gharabaghi A. Subthalamic stimulation modulates cortical motor network activity and synchronization in Parkinson's disease. Brain. 2015 Mar; 138(Pt 3):679-93.
-
Tramontana MG, Molinari AL, Konrad PE, Davis TL, Wylie SA, Neimat JS, May AT, Phibbs FT, Hedera P, Gill CE, Salomon RM, Wang L, Song Y, Charles D. Neuropsychological effects of deep brain stimulation in subjects with early stage Parkinson's disease in a randomized clinical trial. J Parkinsons Dis. 2015; 5(1):151-63.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|